RxDoctor Payments Data

Stephanie Derouin

Nurse Practitioner · Tallahassee, FLNPI 1588102081

Payments from drug & device makers

$2,619in general payments, 2019–2025

Across 122 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$501
  • AbbVie$403
  • Sumitomo Pharma America, Inc.$382
  • Pfizer$326
  • Coloplast$199
  • Ferring Pharmaceuticals Inc.$109
  • plus $699 from 15 others

What the payments were for

  • Food & beverage$2,51996%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,619 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$44,393
Medicare patients
256
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron126$101,114
MyrbetriqMirabegron113$85,086
Tolterodine Tartrate ErTolterodine Tartrate38$3,035
Estradiol46$2,984
Trimethoprim44$2,876
NitrofurantoinNitrofurantoin Macrocrystal35$2,210
Trospium Chloride19$1,912
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst91$1,750
Solifenacin Succinate31$1,217
Tamsulosin Hcl82$1,186
ProgesteroneProgesterone, Micronized31$934
Cephalexin32$740
Ciprofloxacin Hcl84$545
Finasteride22$252
Doxycycline Hyclate27$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$382$101,114126 claims
Astellas Pharma US IncMyrbetriq$501$85,086113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →